<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ruleSet xmlns="http://semanticbits.com/rules/brxml"><id>6ffe8b72-e3db-4499-ad71-4c9178d2d426</id><name>gov.nih.nci.cabig.caaers.rules.sponsor.study.n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma.cancer_therapy_evaluation_program.mandatory_sections_rules</name><description>Mandatory Sections Rules</description><subject>Sponsor defined rules for a study||Cancer Therapy Evaluation Program||N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</subject><coverage>Enabled</coverage><import>gov.nih.nci.cabig.caaers.domain.*</import><rule id="1b6d8c9c-d19b-4ebf-ba96-dc3cc3318762"><condition><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="study" display-uri="Study"><field-constraint grammer-prefix=" Study Agent IND Holder " grammer-postfix="" field-name="investigationalNewDrugIndicator" display-uri="undefined"><literal-restriction evaluator="==" display-uri="is "><value>Cancer Therapy Evaluation Program</value><readable-value>Cancer Therapy Evaluation Program</readable-value></literal-restriction></field-constraint><expression>factResolver.assertFact(study,'gov.nih.nci.cabig.caaers.domain.InvestigationalNewDrug','holderName','runTimeValue','runTimeOperator')</expression></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="study" display-uri="Study"><field-constraint grammer-prefix=" Study Therapy " grammer-postfix="" field-name="studyTherapy" display-uri="undefined"><literal-restriction evaluator="==" display-uri="is "><value>Drug Administration</value><readable-value>Agent,</readable-value></literal-restriction></field-constraint><expression>factResolver.assertFact(study,'gov.nih.nci.cabig.caaers.domain.StudyTherapyType','studyTherapyType','runTimeValue','runTimeOperator')</expression></column><column object-type="gov.nih.nci.cabig.caaers.domain.report.ReportDefinition" identifier="reportDefinition" display-uri="Report Definition"><field-constraint grammer-prefix=" Report Definition " grammer-postfix="" field-name="reportDefinitionName" display-uri="undefined"><literal-restriction evaluator="==" display-uri="is "><value>CTEP 10 Calendar Day SAE Report</value><value>CTEP 5 Calendar Day SAE Report</value><readable-value>CTEP 5 Calendar Day SAE Report,CTEP 10 Calendar Day SAE                            Report</readable-value></literal-restriction></field-constraint><expression>factResolver.assertFact(reportDefinition,null,'name','runTimeValue','runTimeOperator')</expression></column><column object-type="com.semanticbits.rules.objectgraph.FactResolver" identifier="factResolver"><field-constraint><literal-restriction/></field-constraint></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="primarySponsorCode"><literal-restriction evaluator="=="><value>Cancer Therapy Evaluation Program</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,"gov.nih.nci.cabig.caaers.domain.Organization","name","Cancer Therapy Evaluation Program","==")</expression></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="shortTitle"><literal-restriction evaluator="=="><value>N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,null,"shortTitle","N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma","==")</expression></column></condition><action>PRIOR_THERAPIES_SECTION</action><readableAction>Prior Therapies</readableAction><metaData packageName="gov.nih.nci.cabig.caaers.rules.sponsor.study.n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma.cancer_therapy_evaluation_program.mandatory_sections_rules" name="Rule-1" description="Setting Description since its mandatory by JBoss Repository config" checkinComment="Initial Version"><category><path>CAAERS_BASE/SPONSOR_DEFINED_STUDY/n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma/cancer_therapy_evaluation_program</path><metaData name="mandatory_sections_rules"/></category></metaData><readableRule><line>IF</line><line>	 &amp;nbsp;&amp;nbsp;&amp;nbsp; Study Agent IND Holder is  'Cancer Therapy Evaluation Program' </line><line>AND</line><line>	 &amp;nbsp;&amp;nbsp;&amp;nbsp; Study Therapy is  'Agent' </line><line>AND</line><line>	 &amp;nbsp;&amp;nbsp;&amp;nbsp; Report Definition is  'CTEP 5 Calendar Day SAE Report'  or 'CTEP 10 Calendar Day SAE                            Report' </line></readableRule></rule><rule id="78327066-913c-438c-b34b-074eb6997d5f"><condition><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="study" display-uri="Study"><field-constraint grammer-prefix=" Study Therapy " grammer-postfix="" field-name="studyTherapy" display-uri="undefined"><literal-restriction evaluator="==" display-uri="is "><value>Drug Administration</value><readable-value>Agent,</readable-value></literal-restriction></field-constraint><expression>factResolver.assertFact(study,'gov.nih.nci.cabig.caaers.domain.StudyTherapyType','studyTherapyType','runTimeValue','runTimeOperator')</expression></column><column object-type="com.semanticbits.rules.objectgraph.FactResolver" identifier="factResolver"><field-constraint><literal-restriction/></field-constraint></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="primarySponsorCode"><literal-restriction evaluator="=="><value>Cancer Therapy Evaluation Program</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,"gov.nih.nci.cabig.caaers.domain.Organization","name","Cancer Therapy Evaluation Program","==")</expression></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="shortTitle"><literal-restriction evaluator="=="><value>N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,null,"shortTitle","N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma","==")</expression></column></condition><action>AGENTS_INTERVENTION_SECTION</action><readableAction>Agents</readableAction><metaData packageName="gov.nih.nci.cabig.caaers.rules.sponsor.study.n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma.cancer_therapy_evaluation_program.mandatory_sections_rules" name="Rule-2" description="Setting Description since its mandatory by JBoss Repository config" checkinComment="Initial Version"><category><path>CAAERS_BASE/SPONSOR_DEFINED_STUDY/n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma/cancer_therapy_evaluation_program</path><metaData name="mandatory_sections_rules"/></category></metaData><readableRule><line>IF</line><line>	 &amp;nbsp;&amp;nbsp;&amp;nbsp; Study Therapy is  'Agent' </line></readableRule></rule><rule id="c7659676-d06a-4518-8b77-520b8b263102"><condition><column object-type="gov.nih.nci.cabig.caaers.domain.report.ReportDefinition" identifier="reportDefinition" display-uri="Report Definition"><field-constraint grammer-prefix=" Report Definition " grammer-postfix="" field-name="reportDefinitionName" display-uri="undefined"><literal-restriction evaluator="==" display-uri="is "><value>Commercial Intervention 3 Day Report</value><value>Commercial Intervention 7 Day AdEERS Report</value><value>Commercial Intervention 24 Hour SAE Notification</value><value>Non-CTEP IND 3 Day Expedited Report</value><value>Non-CTEP IND 7 Calendar Day Report</value><value>Non-CTEP IND 24 Hour SAE Notification</value><value>CTEP 24 Hour SAE Notification</value><value>CTEP 10 Calendar Day SAE Report</value><value>CTEP 5 Calendar Day SAE Report</value><value>CTEP Commercial Intervention SAE Report</value><readable-value>Commercial Intervention 3 Day Report,Commercial Intervention 7 Day AdEERS Report,Commercial Intervention 24 Hour SAE Notification,Non-CTEP IND 3 Day Expedited Report,Non-CTEP IND 7 Calendar Day Report,Non-CTEP IND 24 Hour SAE Notification,CTEP 24 Hour SAE Notification,CTEP 10 Calendar Day SAE Report,CTEP 5 Calendar Day SAE Report,CTEP Commercial Intervention SAE Report</readable-value></literal-restriction></field-constraint><expression>factResolver.assertFact(reportDefinition,null,'name','runTimeValue','runTimeOperator')</expression></column><column object-type="com.semanticbits.rules.objectgraph.FactResolver" identifier="factResolver"><field-constraint><literal-restriction/></field-constraint></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="primarySponsorCode"><literal-restriction evaluator="=="><value>Cancer Therapy Evaluation Program</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,"gov.nih.nci.cabig.caaers.domain.Organization","name","Cancer Therapy Evaluation Program","==")</expression></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="shortTitle"><literal-restriction evaluator="=="><value>N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,null,"shortTitle","N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma","==")</expression></column></condition><action>BASICS_SECTION</action><action>ADVERSE_EVENT_SECTION</action><action>REPORTER_INFO_SECTION</action><action>DESCRIPTION_SECTION</action><action>STUDY_INTERVENTIONS</action><action>MEDICAL_INFO_SECTION</action><action>TREATMENT_INFO_SECTION</action><action>ATTRIBUTION_SECTION</action><action>SUBMIT_REPORT_SECTION</action><readableAction>Adverse Events</readableAction><readableAction>Adverse Events</readableAction><readableAction>Reporter</readableAction><readableAction>Describe Event</readableAction><readableAction>Study Interventions</readableAction><readableAction>Subject Details</readableAction><readableAction>Course</readableAction><readableAction>Attribution</readableAction><readableAction>Review &amp; Submit</readableAction><metaData packageName="gov.nih.nci.cabig.caaers.rules.sponsor.study.n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma.cancer_therapy_evaluation_program.mandatory_sections_rules" name="Rule-3" description="Setting Description since its mandatory by JBoss Repository config" checkinComment="Initial Version"><category><path>CAAERS_BASE/SPONSOR_DEFINED_STUDY/n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma/cancer_therapy_evaluation_program</path><metaData name="mandatory_sections_rules"/></category></metaData><readableRule><line>IF</line><line>	 &amp;nbsp;&amp;nbsp;&amp;nbsp; Report Definition is  'Commercial Intervention 3 Day Report'  or 'Commercial Intervention 7 Day AdEERS Report'  or 'Commercial Intervention 24 Hour SAE Notification'  or 'Non-CTEP IND 3 Day Expedited Report'  or 'Non-CTEP IND 7 Calendar Day Report'  or 'Non-CTEP IND 24 Hour SAE Notification'  or 'CTEP 24 Hour SAE Notification'  or 'CTEP 10 Calendar Day SAE Report'  or 'CTEP 5 Calendar Day SAE Report'  or 'CTEP Commercial Intervention SAE Report' </line></readableRule></rule><rule id="9f44fa3c-9513-4b04-8655-12492e2979bb"><condition><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="study" display-uri="Study"><field-constraint grammer-prefix=" Study Therapy " grammer-postfix="" field-name="studyTherapy" display-uri="undefined"><literal-restriction evaluator="==" display-uri="is "><value>Device</value><readable-value>Device,</readable-value></literal-restriction></field-constraint><expression>factResolver.assertFact(study,'gov.nih.nci.cabig.caaers.domain.StudyTherapyType','studyTherapyType','runTimeValue','runTimeOperator')</expression></column><column object-type="com.semanticbits.rules.objectgraph.FactResolver" identifier="factResolver"><field-constraint><literal-restriction/></field-constraint></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="primarySponsorCode"><literal-restriction evaluator="=="><value>Cancer Therapy Evaluation Program</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,"gov.nih.nci.cabig.caaers.domain.Organization","name","Cancer Therapy Evaluation Program","==")</expression></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="shortTitle"><literal-restriction evaluator="=="><value>N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,null,"shortTitle","N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma","==")</expression></column></condition><action>MEDICAL_DEVICE_SECTION</action><readableAction>Device</readableAction><metaData packageName="gov.nih.nci.cabig.caaers.rules.sponsor.study.n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma.cancer_therapy_evaluation_program.mandatory_sections_rules" name="Rule-4" description="Setting Description since its mandatory by JBoss Repository config" checkinComment="Initial Version"><category><path>CAAERS_BASE/SPONSOR_DEFINED_STUDY/n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma/cancer_therapy_evaluation_program</path><metaData name="mandatory_sections_rules"/></category></metaData><readableRule><line>IF</line><line>	 &amp;nbsp;&amp;nbsp;&amp;nbsp; Study Therapy is  'Device' </line></readableRule></rule><rule id="878ee598-c7f3-4e25-adc1-01f1c72c6ec4"><condition><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="study" display-uri="Study"><field-constraint grammer-prefix=" Study Therapy " grammer-postfix="" field-name="studyTherapy" display-uri="undefined"><literal-restriction evaluator="==" display-uri="is "><value>Radiation</value><readable-value>Radiation,</readable-value></literal-restriction></field-constraint><expression>factResolver.assertFact(study,'gov.nih.nci.cabig.caaers.domain.StudyTherapyType','studyTherapyType','runTimeValue','runTimeOperator')</expression></column><column object-type="com.semanticbits.rules.objectgraph.FactResolver" identifier="factResolver"><field-constraint><literal-restriction/></field-constraint></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="primarySponsorCode"><literal-restriction evaluator="=="><value>Cancer Therapy Evaluation Program</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,"gov.nih.nci.cabig.caaers.domain.Organization","name","Cancer Therapy Evaluation Program","==")</expression></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="shortTitle"><literal-restriction evaluator="=="><value>N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,null,"shortTitle","N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma","==")</expression></column></condition><action>RADIATION_INTERVENTION_SECTION</action><readableAction>Radiation</readableAction><metaData packageName="gov.nih.nci.cabig.caaers.rules.sponsor.study.n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma.cancer_therapy_evaluation_program.mandatory_sections_rules" name="Rule-5" description="Setting Description since its mandatory by JBoss Repository config" checkinComment="Initial Version"><category><path>CAAERS_BASE/SPONSOR_DEFINED_STUDY/n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma/cancer_therapy_evaluation_program</path><metaData name="mandatory_sections_rules"/></category></metaData><readableRule><line>IF</line><line>	 &amp;nbsp;&amp;nbsp;&amp;nbsp; Study Therapy is  'Radiation' </line></readableRule></rule><rule id="07676072-4e5c-4447-86a0-da727e705531"><condition><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="study" display-uri="Study"><field-constraint grammer-prefix=" Study Therapy " grammer-postfix="" field-name="studyTherapy" display-uri="undefined"><literal-restriction evaluator="==" display-uri="is "><value>Surgery</value><readable-value>Surgery,</readable-value></literal-restriction></field-constraint><expression>factResolver.assertFact(study,'gov.nih.nci.cabig.caaers.domain.StudyTherapyType','studyTherapyType','runTimeValue','runTimeOperator')</expression></column><column object-type="com.semanticbits.rules.objectgraph.FactResolver" identifier="factResolver"><field-constraint><literal-restriction/></field-constraint></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="primarySponsorCode"><literal-restriction evaluator="=="><value>Cancer Therapy Evaluation Program</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,"gov.nih.nci.cabig.caaers.domain.Organization","name","Cancer Therapy Evaluation Program","==")</expression></column><column object-type="gov.nih.nci.cabig.caaers.domain.Study" identifier="studySDO"><field-constraint field-name="shortTitle"><literal-restriction evaluator="=="><value>N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma</value></literal-restriction></field-constraint><expression>factResolver.assertFact(studySDO,null,"shortTitle","N0543, A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma","==")</expression></column></condition><action>SURGERY_INTERVENTION_SECTION</action><readableAction>Surgery</readableAction><metaData packageName="gov.nih.nci.cabig.caaers.rules.sponsor.study.n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma.cancer_therapy_evaluation_program.mandatory_sections_rules" name="Rule-6" description="Setting Description since its mandatory by JBoss Repository config" checkinComment="Initial Version"><category><path>CAAERS_BASE/SPONSOR_DEFINED_STUDY/n0543__a_phase_ii_trial_of_pharmacogenetic_based_dosing_of_irinotecan__oxaliplatin__and_capecitabine_as_first_line_therapy_for_advanced_small_bowel_adenocarcinoma/cancer_therapy_evaluation_program</path><metaData name="mandatory_sections_rules"/></category></metaData><readableRule><line>IF</line><line>	 &amp;nbsp;&amp;nbsp;&amp;nbsp; Study Therapy is  'Surgery' </line></readableRule></rule></ruleSet>

